PXT3003 at High Dose Shows Potential to Safely Treat CMT1A in Phase 3 Trial

PXT3003 at High Dose Shows Potential to Safely Treat CMT1A in Phase 3 Trial

310020

PXT3003 at High Dose Shows Potential to Safely Treat CMT1A in Phase 3 Trial

PXT3003, a potential treatment for Charcot–Marie–Tooth type 1A (CMT1A) being developed by Pharnext, showed “promising” results and good safety at high dose in a recently completed first Phase 3 clinical trial, researchers reported. The therapy was found to ease disabilities in those affected by the disease, based on scores in the overall neuropathy limitations scale (ONLS), a way of assessing limitations in upper and lower limbs in everyday activities. But the high-dose group in the PLEO-CMT…

You must be logged in to read/download the full post.